1. Scrip
  2. >>Conferences
  3. >>ASH

ASH: Roche Looks To Fixed-Duration Edge In Bispecifics Battle

 
• By Andrew McConaghie

Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab’s Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.

Roche_Logo_Glass

Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.

The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By Kevin Grogan

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 
• By Alaric DeArment

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from Therapy Areas

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.